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Abstract Psoriatic arthritis (PsA) is a chronic inflammatory
joint disease affecting around 40% of psoriasis patients.
Minimal disease activity (MDA) criteria have been proposed
to identify a state of low disease activity, one of the principal
goals of treatment for psoriatic disease. This study investigat-
ed treatment with ustekinumab (UST) in the context of a real-
world setting. Thirty-four PsA patients who had failure or
inadequate response to conventional synthetic disease-
modifying antirheumatic drugs or to anti-tumour necrosis fac-
tor alpha were enrolled. Demographic and clinical features,
MDA criteria, and the impact of psoriatic skin manifestations
on patients’ quality of life (QoL) using the dermatology life
quality index (DLQI) questionnaire were evaluated at baseline
and after 24-week treatment. Adverse events were recorded.
At week 24, 70.5% of patients (n = 24) achievedMDA. A sub-
analysis of dermatological indices of the MDA criteria
showed that the psoriasis area severity index score was signif-
icantly improved and body surface area was significantly de-
creased at 24 weeks compared with that at baseline (both
p < 0.001). For the rheumatologic indexes, tender joint count,
swollen joint count, and tender entheseal points were all sig-
nificantly improved at 24 weeks of therapy (all p < 0.01 vs.
baseline). Mean DLQI value decreased approximately four-
fold, and there were no safety concerns. The achievement of
MDA as well as the significant improvement in DLQI and
lack of adverse events in the context of a real-life setting
shown here confirms the efficacy and safety of UST in PsA.
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Introduction
Psoriatic arthritis (PsA), a chronic inflammatory joint disease
which occurs in up to 40% of patients suffering from psoriasis
[1, 2], can be variably associated with extra-cutaneous comor-
bidities [3–6]. Arthritis, dactylitis, enthesitis, and involvement
of the axial skeleton in the form of sacroiliitis and spondylitis,
in combination with a positive personal or family history of
psoriasis, represent the main aspects for addressing disease
diagnosis [7–10].
PsA is also associated with a variable grade of functional
impairment, which is responsible for poor quality of life
(QoL) due to its negative impact on patients’ psychological
functioning and daily living activities [11, 12].
The principal goals of psoriatic disease treatment are the
achievement of clinical remission or low disease activity, the
inhibition of structural damage, and the improvement of pa-
tients’ QoL [13, 14]. However, there are no clear criteria for
defining remission in PsA. In 2010, minimal disease activity
(MDA) criteria were introduced to identify a state of low dis-
ease activity [15, 16]; patients are classified as achieving
MDA if they fulfil at least five out of the sevenMDA outcome
measures.
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An increased understanding of the inflammatory pathways
involved in psoriatic disease has improved therapeutic strate-
gies due to the introduction of agents directed against specific
molecular targets, such as the tumour necrosis factor alpha
(TNF-α) and interleukin (IL)-12/IL-23 [17–20]. In particular,
the biological drug ustekinumab (UST) is a fully human
monoclonal antibody that binds with high specificity and af-
finity to the p40 subunit shared by IL-12 and IL-23, which are
essential components of the T helper (Th)1 and Th17 inflam-
matory pathways and key mediators in both psoriasis and PsA
pathogenesis [21]. Similarly to TNF-α antagonists, several
clinical trials have shown UST to be efficacious in treating
articular as well as cutaneous aspects of psoriasis and in
inhibiting structural damage progression [22–28]. Moreover,
both anti-TNF-α and anti-IL-12/23 have proven to be effec-
tive and safe in children and in the elderly population [29–31].
Although randomized clinical trials are the gold standard in
evaluating the effects of treatments, they are conducted under
rigorously controlled settings and may not be generalizable
across practical, real-world situations, where conditions differ
significantly from the trial context [32]. Hence, the essential
role of real-world studies in the assessment of drugs is increas-
ingly recognized, even if data collected under real-life practice
circumstances are still lacking for PsA therapies.
The present real-world study aimed firstly to investigate the
achievement of MDA after 24-week treatment with UST in
patients with active PsA and secondly to evaluate the derma-
tology life quality index (DLQI).
Methods
Patients
An observational study was conducted in a cohort of PsA
patients at their first use of UST. Patients were enrolled from
those attending the Dermatology and Rheumatology Units of
the University of Naples BFederico II^ from January to
December 2015. The study protocol followed the principles
of the Declaration of Helsinki and all patients provided their
written informed consent prior to participation.
Eligible participants were consecutive adult patients
(≥18 years of age) of both sexes, with a diagnosis of PsA
classified on the basis of the Classification Criteria for
Psoriatic Arthritis (CASPAR) criteria [9], who had failed or
had an inadequate response to conventional synthetic disease-
modifying antirheumatic drugs (csDMARDs) or to anti-
TNF-α. Failure or inadequate response was defined as the
presence of at least three swollen joints (SJC) ≥3 and three
tender joints (TJC) ≥3. Exclusion criteria included contraindi-
cations to UST use [33] and previous treatment with UST for
psoriasis or PsA.
All patients were treated with UST 45 or 90 mg (based on
weight ≤100 or >100 kg, respectively) subcutaneous injection,
administered at weeks 0 and 4, then every 12 weeks, accord-
ing to the manufacturers’ instructions [33].
At baseline (W0), patients’ demographic and clinical fea-
tures were recorded, focusing on age, gender, vital signs, fam-
ily and personal medical history, comorbidities, PsA clinical
subset and disease duration, and previous and/or actual anti-
psoriatic therapies (including anti-TNF-α, csDMARDs, and
steroids).
Clinically important aspects of the disease, such as arthritis,
psoriasis, enthesitis, pain, patient-assessed global disease ac-
tivity, and physical functions, were evaluated through out-
come measures of MDA criteria as follows: TJC, SJC, psori-
asis activity and severity index (PASI), body surface area
(BSA), patient pain visual analogic scale (VAS), patient global
assessment of disease activity (PtGA), health assessment
questionnaire (HAQ), and tender entheseal points.
Erythrocyte sedimentation rate (ESR) and C-reactive protein
(CRP) were also recorded at week 0 and week 24.
In addition, the DLQI questionnaire was used to assess the
impact of skin manifestations of psoriasis on a patients’ QoL
over the previous week (on a scale of 0–30) [34]. Both MDA
and DLQI outcomes were collected at baseline and after 24-
week treatment. In order to evaluate the safety profile of UST,
the appearance of adverse events was also recorded during this
period.
Statistical analysis
The Mann-Whitney test was used to calculate statistical dif-
ferences between baseline and week 24. p values <0.05 were
considered to be statistically significant. All statistical analy-
ses were performed using GraphPad Prism 4.0 (GraphPad
Software Inc., La Jolla, CA, USA).
Results
Thirty-four patients (23 males, 11 females; mean age
53.4 years) with active PsAwere enrolled. The mean duration
of PsAwas 8.8 years. For the PsA clinical subsets, 26 patients
(76.5%) showed a predominant peripheral involvement; the
most common clinical form was oligo-arthritis (12 patients;
34.3%), followed by enthesitis (7 patients; 20.6%), dactylitis
(4 patients; 11.8%), and both dactylitis and enthesitis (3 pa-
tients; 8.8%). Only eight patients (23.5%) had predominance
of axial disease. Previous treatments included csDMARDs
and anti-TNF-α biological drugs. Notably, all 34 patients
had experienced therapy with at least one csDMARD; 21
patients (61.7%) had received treatment with two
csDMARDs and only 1 patient (2.9%) had undergone therapy
with three csDMARDs. The most widely used csDMARD
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was methotrexate (28 patients; 82.3%), followed by cyclo-
sporine (24 patients; 70.5%), and sulfasalazine (4 patients;
11.7%). For prior anti-TNF-α biologic therapy, 24 patients
(70.5%) had been treated with at least one agent, whereas 6
(17.4%) and 10 (29.4%) patients had been managed with two
or three different biologics, respectively.
Twenty-four patients (70.5%) achieved MDA after 24-
week treatment with UST (W24) (Fig. 1). A sub-analysis of
dermatological indices of the MDA criteria showed that the
PASI score was significantly improved and BSAwas signifi-
cantly decreased at 24 weeks compared with that at baseline
(both p < 0.001) (Table 1). For the rheumatologic indexes,
TJC, SJC, and tender entheseal points were all significantly
improved at 24 weeks of therapy (all p < 0.01 vs. baseline)
(Table 1). There was also a significant improvement in patient
pain VAS, PtGA, and HAQ after 24-week treatment with UST
(all p < 0.01 vs. baseline), as reported by the patients’ self-
assessment of their disease (Table 1).
There was a significant difference between the levels of
CRP from week 0 (median CRP level 2.01 ± 2.7 mg/dl) to
week 24 (versus median CRP level 0.57 ± 0.8 mg/dl)
(p < 0.01). Regarding the levels of ESR, there was also an
improvement from week 0 (median ESR level 24 ± 21.48) to
week 24 (versus median ESR level 16.6 ± 13.9) (p = n.s.).
In addition, there was a significant decrease in the impact of
skin manifestations of psoriasis on a patients’ QoL based on
the DLQI questionnaire after 24-week treatment with UST
compared with that at baseline (16.6 vs. 4.3, p < 0.001). No
adverse events were reported during the treatment period.
Discussion
Patients with PsA can be refractory or show loss of response to
csDMARDs and anti-TNF-α therapy [35]. The switch to the
anti-IL-12/23 p40 monoclonal antibody UST has been shown
to be an efficacious and safe therapeutic strategy in random-
ized clinical trials [22–26]. Observational cohort studies can
be useful to implement data gained from these trials. In this
survey, we evaluated the efficacy and safety of UST in PsA
patients in the context of a real-world setting. To the best of
our knowledge, this is the first study which has applied the
MDA criteria, which have already been validated as disease-
specific indicators of disease activity [15, 16], for evaluating
the efficacy of UST in PsA subjects. Our results showed that
24-week treatment with USTwas efficacious for the majority
of patients with active PsA, with approximately 70% of pa-
tients achieving a low disease activity state, as defined by the
MDA criteria. Moreover, the approximately fourfold decrease
in DLQI score as well as the statistically significant improve-
ment in HAQ value at week 24 compared with that at baseline
suggests that patients experienced an improvement in their
QoL. It is well known that both psoriasis and PsA can nega-
tively impact on QoL, limiting daily life and working perfor-
mances, resulting in restrictions to social and recreational ac-
tivities as well as productive life, with patients with concom-
itant PsA being affected to a much greater degree [11, 36, 37].
Therefore, improving QoL should be considered one of the
major objectives of psoriasis and PsA treatments. While this
fact is already highlighted in the dermatological literature by
studies which considered QoL (evaluated by the DLQI ques-
tionnaire) as a major criterion for the introduction of systemic
agents in patients with mild psoriasis [38–40], there is a scar-
city of attention on this topic in the rheumatologic literature,
especially regarding mild or limited forms of disease.
We propose that the DLQI questionnaire should be added
to the MDA criteria since PsA usually develops after psoriasis
so that articular involvement and skin lesions often coexist in
the same patient. Whilst the HAQ focuses on the impact of
Fig. 1 The percentage of patients achieving minimal disease activity
(MDA) at week 24
Table 1 Outcome measures (mean ± SD) of minimal disease activity
(MDA) criteria at baseline (W0) and after 24-week (W24) treatment with
ustekinumab
MDA criteria W0 W24 p value
TJC (0–68) 7.0 ± 4.2 1.6 ± 1.4 0.001
SJC (0–66) 1.5 ± 1.5 0.3 ± 0.5 0.01
PASI (0–72) 15.4 ± 9.5 1.8 ± 4.2 0.001
BSA (%) 58 ± 17.2 3 ± 10.5 0.001
Patient pain VAS (0–100 mm) 53 ± 18.4 9.6 ± 7.6 0.01
PtGA (0–100 mm) 58.1 ± 15.8 10.3 ± 7.9 0.01
HAQ (0–3) 1.2 ± 0.8 0.1 ± 0.4 0.01
Tender entheseal points (0–13) 2.1 ± 3.5 0.5 ± 1.2 0.01
MDA (%) 0 70.5 0.01
BSA body surface area, HAQ health assessment questionnaire, PASI pso-
riasis activity and severity index, PtGA patient global assessment of dis-
ease activity, SD standard deviation, SJC swollen joint count, TJC tender
joint count, VAS visual analogic scale, MDA minimal disease activity.
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PsA on daily life activities (such as walking, dressing up,
washing hair, and lifting weights), the DLQI assesses the im-
pact of skin appearance (scaling, erythema) and symptom-
related (itch, burning sensation) impairment on everyday life.
Indeed, using both the HAQ and DLQI questionnaires may
better define a state ofMDA in PsA patients since they usually
show both aspects (cutaneous and articular) of the psoriatic
disease.
In our real-world study, there were no concerns regarding
the safety profile of UST, which is in keeping with results
from its use in clinical trials on PsA, including randomized
trials [22–28]. However, our study has limitations due to its
small sample size, lack of instrumental evaluation of patients’
involved joints, and the short duration (24 weeks) of both UST
treatment and MDA criteria assessment, which may restrict
generalization of the results.
In conclusion, the achievement of MDA as well as the
significant improvement in DLQI and lack of adverse events
in the context of a real-life setting shown here confirms the
efficacy and safety of UST in PsA. This study adds strength to
the possibility of a therapeutic switch to the anti-IL-12/23 p40
monoclonal antibody in PsA patients with failure or inade-
quate response to csDMARDs or anti-TNF-α drugs. Further
real-world studies to evaluate MDA criteria are needed to
assess the long-term effects of UST in PsA treatment, with
emphasis on its impact on QoL using specific indices such
as the DLQI. Ultimately, achieving a state of well-being and
good QoL should be considered as one of the major objectives
for the treatment of psoriasis and PsA.
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